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Cardiovascular  disease  (CVD)  remains  the  leading  cause  of  death  globally.  A class  of med-
ications,  known  as  statins,  lowers  low-density  lipoprotein  cholesterol  levels,  which  are
associated with  CVD.  The newest  2013 U.S.  cholesterol  guideline  contains  an  assessment
of  risk  that  greatly  expands  the  number  of  individuals  without  CVD  for  whom  statins  are
recommended.  Other  countries  are  also  moving  in  this  direction.  This  article  examines  the
controversy  surrounding  these  guidelines  using  the  2013  cholesterol  guidelines  as  a case
study  of  broader  trends  in clinical  guidelines  to  use  a  narrow  evidence  base,  expand  the
boundaries  of disease  and  overemphasize  pharmaceutical  treatment.
We ﬁnd  that  the recommendation  in  the 2013  cholesterol  guidelines  to  initiate  statins
in individuals  with  a lower  risk  of CVD  is  controversial  and  there  is  much  disagreement
on  whether  there  is evidence  for  the guideline  change.  We  note  that,  in  general,  clinical
guidelines  may  use  evidence  that  has  a number  of biases,  are  subject  to conﬂicts  of  interest
at  multiple  levels,  and  often  do not  include  unpublished  research.  Further,  guidelines  may
contribute to the  “medicalization”  or  “pharmaceuticalization”  of  healthcare.
Speciﬁc  policy  recommendations  to improve  clinical  guidelines  are  indicated:  these
include  improving  the  evidence  base,  establishing  a public  registry  of  all results,  including
unpublished  ones,  and  freeing  the research  process  from  pharmaceutical  sector  control.
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Cardiovascular disease (CVD) remains the leading cause
of death globally, and prevention of CVD is a priority in
world health systems. Prevention focuses on the reduc-
tion of risk factors such as an unhealthy diet, inadequate
exercise, obesity, and smoking, as well as reduction in total
blood cholesterol and the low density lipoprotein (LDL)
portion of cholesterol.Several decades ago a class of pharmaceuticals, HMG-
CoA reductase inhibitors – commonly known as statins –
were found to have a signiﬁcant impact on cholesterol,
particularly LDL. Statins have been recommended for both
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secondary prevention of CVD (individuals with known CVD,
so prevention focuses on reducing further development of
the disease and complications), and primary prevention
(those without CVD but with risk factors for the disease,
including certain levels of cholesterol or LDL). Since their
entry into the U.S. market in 1987, the utilization of statins
has skyrocketed. Between 2007 and 2010 statins were the
most commonly prescribed therapeutic class in the U.S.
[143]. According to the U.S. Centers for Disease Control and
Prevention, in the last two decades statin use in the U.S.
increased seven-fold among adults age 45–64 [1].
Statin utilization has been guided by clinical protocols.
In the U.S., the National Cholesterol Education Program
issued Adult Treatment Protocol (ATP) reports in 1988,
1993 and 2001, each one recommending a successively
broader application of statins to the population [2]. The
newest guidelines in the U.S., issued in 2013 by the
American College of Cardiology and the American Heart
Association (ACC/AHA), simpliﬁed some of the older guide-
lines and added risk categories [3]. More importantly,
however, they contain a controversial new threshold and
calculation of risk that would greatly expand the number
of individuals that should be placed on statins [4].
A thorough understanding of this controversy has
become even more important given two new lipid-
lowering medications, Repatha (Evolocumab) and Praluent
(Alirocumab), approved by the U.S. Food and Drug Adminis-
tration (FDA) for marketing. Medications in this new class
(PCSK-9 inhibitors) appear to be capable of lowering LDL
below even that of statins, and (in a post hoc study) of
reducing the incidence of cardiovascular disease [5]. They
are being promoted for the care of patients whose LDLs
are not adequately lowered by statins, and for those who
do not stay on statins due to their side effects. However,
to date, the effects of the new medications are based on
just a few trial studies with surrogate outcomes [5], and
the medications are far more expensive than statins [6].
If the 2013 guidelines become widely accepted and lipid-
lowering continues to be called for in low-risk individuals,
it is very possible that the new class of medications will be
necessary to achieve that lowering and could become part
of the next generation of lipid-lowering guidelines.
This article examines the controversy surrounding the
2013 cholesterol guidelines. We  use cholesterol guidelines
as a case study to address the broader issues of clinical
guideline development, including the quality of evidence
and conﬂicts of interest embedded in guideline recommen-
dations. The evidence presented suggests a link between
the clinical guideline evidence-base and the expansion of
disease categories, “medicalization” and “pharmaceutical-
ization” of health and illness in the U.S. and other countries.
Policies are recommended for future clinical guideline
development.
1. 2013 U.S. guideline controversy
The 2013 ACC/AHA cholesterol guidelines recommend
statins for both secondary and primary prevention of CVD.
For secondary prevention the guidelines recommend statin
use in anyone who has had heart or peripheral vascular
disease, angina, heart bypass or angioplasty, and stroke or120 (2016) 797–808
transient stroke (TIA) [3]. Statins are recommended for pri-
mary prevention for those: between 40 and 75 years of
age with type 1 or 2 diabetes; over 21 years of age with
LDL of 190 mg/dl or more; and 40–75 years of age with a
7.5 percent or higher risk of developing CVD (heart attack
or stroke) within 10 years. The risk calculator is based on
age, gender, race, total cholesterol, High Density Lipopro-
tein (HDL), systolic blood pressure level, and current blood
pressure medication status [3].
It is mainly the calculation of risk and the recommen-
dation for starting statin therapy for primary prevention
at ≥7.5 per cent risk of CVD within 10 years that has been
controversial. Several studies show that the risk calcula-
tor overestimates the risk of CVD by 50% or more [7–10].
As far as the threshold, some consider it to be “aggres-
sive,” and point out that guidelines in other countries have
higher thresholds, as for example the most recent ones in
the U.K. and Australia, which are set at 10% over 10 years
and 10–15% over 5 years respectively [11]. Estimates indi-
cate that this aspect of the U.S. guidelines would broaden
the use of statins for those between the ages of 40 and 75 by
25–30% [4,12,13]. In practical terms, it is estimated that the
new guidelines would recommend statin therapy for nearly
all men  > 60, women > 69 years [7,14], and all African Amer-
ican men  over the age of 65 with normal blood pressure and
cholesterol levels [15].
Proponents of the 2013 guidelines point out that the rec-
ommendations for statin use in lower risk populations are
based on randomized controlled trials (RCTs) of statin efﬁ-
cacy. Two large meta-analyses of statin RCTs, both before
[16] and after [17] the guideline change, also support the
change. The ﬁrst review, published in 2012 by the Choles-
terol Treatment Trialists’ Group (CTT), found that in low risk
individuals (ﬁve-year risk of major vascular events <10%)
a reduction in LDL due to statins was associated with an
absolute reduction in the risk of major vascular events and
all-cause mortality. The second review, published in 2014
in the Cochrane Collection of Systematic Analyses, used
study-level results, including those from the CTT analysis,
and found that non-fatal CVD events and all-cause mor-
tality were reduced with the use of statins in individuals
with no prior history of CVD. Some post-guideline studies
have found the new guidelines to be better at predicting
indicators of CVD such as blood vessel plaque [18,19] and
coronary artery calciﬁcation [20], and to be more accurate
in identifying increased risk of CVD incidents, particularly
in intermediate-risk participants [20].
These studies represent a degree of support for the
new guidelines, but critics of the guidelines charge that
there are a number of issues with this evidence. First, the
risk categories in the 2013 guidelines are not the same as
those studied in RCTs, including the meta-analyses, so it
is impossible to apply outcomes in the studies to individ-
uals under the new guidelines. Second, while RCTs have
found statins to be efﬁcacious for those with CVD or high
risk of CVD, there is less evidence that they are effective in
lower risk populations, especially older adults [2,21–24].
This is especially true for the most important outcomes
of statin therapy – lower all-cause mortality, few side
effects or adverse events, and positive patient-reported
outcomes such as good quality of life [22,25]. CTT claims of
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tatins reducing all-cause mortality in low risk individuals
ave been challenged by other researchers who recalcu-
ated their results and did not ﬁnd this [22,25]. Neither
eta-analysis examined patient-reported quality of life or
dequately reported common side effects such as mus-
le disorders [22,26–31] or less common adverse reactions
22,32–41]. These issues may  not be adequately discovered
n clinical trials because they are designed more to test
or efﬁcacy than to catch adverse reactions, and individ-
als who are less likely to beneﬁt and more likely to have
dverse reactions may  be excluded from the RCT sample
22,28,42]. Further, individuals experiencing side effects in
CTs tend to drop out, so their negative experience is not
ecorded [22], and the length of many RCTs may  be too
hort to observe side effects [28].
A third concern regarding the evidence for the 2013
uidelines is that, in general, the effectiveness of statins
ends to be overstated. A common way this occurs is to
eport relative risk, rather than absolute risk [2,21], as
as the case with the Cochrane Collection meta-analysis.
lso, RCTs examine efﬁcaciousness rather than effective-
ess; that is, they show the effect on a narrower sample of
ndividuals than occurs in the “real world.”
A fourth concern involves data transparency. The
ochrane review analyzed published studies available to
hem, and did not include any unpublished data from the
linical trials. Therefore, the review could suffer from pub-
ication bias – negative studies that were never published
nd therefore were not included in the analysis [43]. The
TT study used patient level data from the team’s studies,
ut whether that included unpublished study results is not
nown and the data have not been made available to other
nvestigators [44].
Another concern is that while the 2013 guidelines for
rimary prevention of CVD instruct providers to promote
ifestyle management in the ≥7.5% risk group as part of
heir discussion with patients, there is no recommenda-
ion for a trial period of just lifestyle changes in this group.
et, there is evidence that a healthy lifestyle should be
n important part, if not the focus of primary prevention,
specially in lower risk categories [45–56]. While it may
e difﬁcult to achieve compliance with this approach (and
or this reason, it is understandable that physicians may
eel that the best thing for their patients is to go straight
o statins), a number of motivational programs have been
eveloped that have shown success in weight loss, other
ifestyle improvements, and/or lowering of cardiovascular
isk [57–64]. The 2013 cholesterol guidelines also do not
ention the importance of socioeconomic status in the
evelopment of CVD. Socioeconomic (SE) factors such as
ducation, employment (or unemployment), occupation,
ork hours, stress, income, neighborhood environment,
arly childhood health, and racial and income inequalities,
ave been found to affect lifestyle behaviors and CVD risk
actors [65–80], as well as CVD directly [81–83,78,84]. The
HA declares that addressing socioeconomic determinants
s the most signiﬁcant opportunity for reducing death and
isability from CVD in the U.S. [85].
Finally, there were conﬂicts of interest (COI) in the
evelopment of the guidelines, from the individual stud-
es, to the meta-analyses, to the guideline committee itself.120 (2016) 797–808 799
In the CTT meta-analysis most of the RCTs were funded by
the manufacturers, members of the CTT writing committee
received funds from the pharmaceutical industry for meet-
ings, and two authors also received speaking honoraria
from the industry [16]. In the Cochrane Collection study,
industry-sponsorship of all of the trials was  acknowledged
in post-report comments but the meta-analysis authors
claimed no COI [17]. As far as the guideline committee,
eight of 15 panelists, including the chair and two co-chairs,
had past or current ties to pharmaceutical companies
[15].
For these reasons, pro and con, practitioners and
researchers are divided on the appropriateness of the pri-
mary prevention portion of the 2013 guidelines. Some
believe that there is sufﬁcient evidence to proceed with the
implementation of these primary prevention guidelines in
the population. Others disagree, and call for more research
which would improve upon the methodological limitations
of existing evidence, and for reforms in the clinical guide-
line development process.
2. Expenditures on statins
Under the new guidelines expenditures related to
statins will increase. Abramson and colleagues [22] esti-
mate that expanding statin use would result in up to $1
USD per person per day in pharmaceutical drug costs.
Expenditures will also rise due to an increase in visits to
physicians to obtain new prescriptions and to follow up on
the progress of statin regimens. Also, the aforementioned
side effects occurring in some individuals will add to health
care costs. Unfortunately, at this time data are not available
to accurately estimate the total costs of the increased statin
use.
These costs must be weighed against the health beneﬁts
and cost savings from a decrease in cardiovascular events.
Pencina and et al. [4] estimate that the new guidelines, if
fully implemented, would reduce such events by 475,000,
but they admit that this is based on a number of assump-
tions, including “the independence of the relative beneﬁt
of statin use from the levels of LDL cholesterol or abso-
lute risk” (p. 1430) [4]. Other researchers are skeptical that
the new guidelines will result in nearly so great a beneﬁt.
Abramson et al. [22] ﬁnd that over ﬁve years only one case
of non-fatal heart attack or stroke would be averted out of
140 lower risk patients. Given the 12.8 million newly eligi-
ble, and allowing for a take-up rate of 58%, that translates
into only 50,000 cases averted. Cost savings would also be
reduced due to adverse events.
To date we  are aware of one cost-effectiveness analy-
sis (CEA) of the 2013 guidelines [86]. This CEA found that
the threshold of 7.5% or higher (with an estimated 48% of
adults treated) had an incremental cost-effectiveness ratio
(ICER) of $37,000/QALY compared with a 10% or higher
threshold. Thresholds of 4.0% or higher (61% of adults
treated) and 3.0% or higher (67% of adults treated) had
ICERs of $81,000/QALY and $140,000/QALY, respectively.
Cost-effectiveness results were sensitive to statin price and
the risk of statin-induced diabetes. The CEA results of the
current threshold were considered to be acceptable.
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The degree to which pharmaceutical companies will
proﬁt from the 2013 cholesterol guidelines is not certain.
Some believe that it will not be signiﬁcant since patent pro-
tections have run out on the medications. However, new
drugs in the class may  be on the horizon that could essen-
tially renew patent protection. Additionally, as Kaplan [2]
points out, the use of drugs for chronic diseases is not like
that of antibiotics where one takes them for a short period
of time. With chronic diseases, the medications are taken
for a lifetime. The more people that are put on drugs for pre-
vention of chronic diseases and the younger they are put
on those medications, the more pharmaceutical companies
proﬁt.
In addition, if other countries follow suit and lower their
guideline thresholds, markets will expand even more. For
example, Muntner et al. [87] estimate that if China adopted
the 2013 U.S. cholesterol guidelines, 33.4 more million Chi-
nese adults should begin statin therapy [87]. If all countries
adopted the U.S. guidelines and CVD risk were similar to the
U.S., close to 1 billion people would be eligible for statin
therapy for primary prevention [88].
Although expenditures to prevent and treat disease
should never be the decisive factor in the development
of clinical guidelines, when accompanied by questions
regarding the efﬁcacy and safety of initiating statins in
low-risk populations, the appropriateness of the 2013
guidelines should come under closer scrutiny.
3. Cholesterol guidelines internationally
Examining the cholesterol guideline policies in other
countries puts US guidelines in perspective. Table 1
presents the primary prevention portion of current choles-
terol guidelines from seven developed countries. The
evidence base and criteria for statin eligibility differ across
countries with most employing all types of studies in their
Table 1
Comparison of statin guidelines in seven developed countries.
Country (latest guideline) Evidence for guidelines Thres
preve
Australia, (HF, 2013) RCTs and meta-analyses of
RCTs
>10–1
Canada (CCS, 2012) Mostly RCTs of statin efﬁcacy Frami
10–20
Europe  (ESC, 2011) All evidence (RCTs,
epidemiological studies, etc.)
≥5% r
calcul
Japan  (JAS, 2002) All evidence (RCTs,
epidemiological studies, etc.)
A cou
LDL: 0
or ≥h
Netherlands (CVRM, 2011) Unable to ascertain for current
guidelines, but policy analysts
advocate utilizing all evidence
Risk o
>2.5 m
15 ye
United Kingdom (NICE, 2014) Unable to ascertain ≥10%
calcul
CVD (
United States (ACC/AHA, 2013) RCTs and meta-analyses of
RCTs
≥7.5%
calcul
Sources: Australia [161]; Canada [162,163]; Europe [147]; Japan [148]; Netherlan120 (2016) 797–808
development. Risk thresholds vary from as low as 5% for
the European (ESC) guidelines to 20% for the Canadian and
Dutch guidelines. The degree to which lifestyle changes are
emphasized also differ, with the Japanese and European
guidelines recommending lifestyle changes before initia-
tion of statins, and the U.S. and Canada recommending a
discussion (but not necessarily a trial of lifestyle changes
ﬁrst).
It is admittedly difﬁcult to rank these guidelines in terms
of agressiveness since each differs in a number of com-
ponents, including calculations of risk. Still, based on the
risk thresholds, the European and U.S. guidelines appear
to be among the most aggressive. Vaucher et al. [89] ﬁnd
that when applied to the Swiss population both the ESC
and ACC/AHA guidelines would increase the number of
individuals eligible for statin therapy, the ACC/AHA guide-
lines more so (it would more than double the prevalence
of high risk individuals) [89]. Another recent study noted
that ACC/AHA guidelines applied to Europe would result in
nearly all men  and two-thirds of women age 55 years or
older being candidates for statin treatment [90].
4. How evidence based are clinical guidelines?
The 2013 cholesterol guidelines were developed using
protocols similar to other clinical guidelines. Developed by
both non-governmental professional societies and govern-
mental agencies [92], clinical guidelines are “systematically
developed statements to assist practitioner and patient
decisions about appropriate health care for speciﬁc clinical
circumstances” [91]. In the U.S., guidelines are predomi-
nantly developed by professional societies, such as the ACC
and AHA,[93] while governmental agencies, such as the
Agency for Healthcare Research and Quality (AHRQ), play
more of a sponsorship and oversight role [94]. In other
countries governmental agencies, such as the National
hold for initiation for primary
ntion
Importance of lifestyle change
in primary prev.
5% risk within 5 years 10–15% risk: encourage
lifestyle change ﬁrst and
review progress in 6–12
months. >15% risk: Lifestyle
change and pharmacological
therapy
ngham risk score ≥20% or
% and LDL ≥ 3.5 mm
Discuss w/those meeting
threshold
isk CVD in 10 years. SCORE Risk
ation, validated
Lifestyle interventions should
be tried ﬁrst
nt of major risk factors other than
 = low risk; 1–2 = intermediate; 3
igh
Statins should be considered
only after 3–6 months lifestyle
change
f CVD ≥20% in 10 years & LDL
mol/l (97 mg dl). If diabetic, add
ars to age for risk calculation
Unable to ascertain
 risk of CVD in 10 years. Risk
ation of factors contributing to
QRISK2)
Discuss w/those meeting
threshold. Consider the
beneﬁts of lifestyle changes in
decision to initiate statins.
 risk CVD in 10 years. Risk
ation may overestimate risk
Discuss w/those meeting
threshold
ds [164]; U.K. [165]; U.S. [3].
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Box 1: Types of bias in clinical research
1. Individual study research design and conduct
• Choice of sample
• Likelihood of fewer comorbidities
[22,23,28,42,92,98]
• Higher probability of positive response to inter-
vention [22,28,42,98]
• May  not include women, minorities, disadvan-
taged, older individuals, children [100]
• Choice of outcomes
• Narrow [92]
• Surrogate endpoints [22,92,100,105]
• Changing outcomes after starting study/data
dredging [92,152]
• Short time horizon [28,92,97]
• Participant attrition [22,97,98]
2. Individual study interpretation and publication
• Selective reporting [98,100]
• Reporting relative risk [2,21,22,100]
• Report signiﬁcance but not clinical effect
[22,92,100,101]
• Failure to report side effects [22,100]
3. Poor external validity – study population is nar-
row or excludes population the intervention will be
given to [21,23,92,98,100,101,103–105]
4. Systematic review or meta-analysis
• Use of studies with biases [98]
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f• Failure to include unpublished results
[42,92,98,101]
nstitute for Health and Clinical Excellence (NICE) in the
.K., play a bigger development role [92].
Clinical guidelines “have become deeply rooted in
he principles of evidence-based medicine“[93] (p. 706),
ith expectations that guideline committees be composed
f clinical and research experts that utilize high-quality
esearch – optimally systematic reviews and meta-
nalyses of RCTs – in their recommendations [92,93].
owever, clinical guidelines are not without issues related
o their evidence base [93,95].
.1. Bias in research evidence
First is the problem of bias in the research evidence.
adad and Enkin [96] list 60 and Warden [97] lists 150 pos-
ible sources of bias in clinical research. Some of the major
nes are listed in Box 1. We  mentioned several of these
iases when discussing the 2013 cholesterol guidelines and
ill not review them again. Sufﬁce it to say that the pres-
nce in a study of any one of these will call into question
he true impact of the intervention, yet studies used to form
linical guidelines often suffer from several of these biases.
The biases common to individual studies carry over
o the systematic reviews and meta-analyses that utilize
hem. These syntheses intend to improve upon the validity
f the individual studies, but they are only as good as the
tudies they synthesize: if the individual studies are biased,
he syntheses will be biased as well [92,98,99]. In addition,
f the syntheses do not detail individual study biases and
imitations, the ﬁnal synthesis appears to be more bias-
ree than it really is. Finally, these syntheses may  not track120 (2016) 797–808 801
down or be able to get at unpublished data and results.
Since unpublished results are likely to be those showing
insigniﬁcance or even negative effects, syntheses that omit
these may  not reﬂect the true impact of the intervention
[92,98].
These systematic reviews and meta-analyses, in turn,
are relied upon by clinical guideline committees that typ-
ically follow a hierarchy of evidence in which systematic
reviews and meta-analyses of RCTs are at the top [92].
Other types of studies will often not be considered or will
be given less consideration, as causation cannot be deter-
mined from those studies. Although RCTs are thought to be
the “gold standard” of clinical research, they have signiﬁ-
cant limitations (in fact, all of the biases in Box 1 may be
present in them) [98,100–104]. On the other hand, what are
limitations with RCTs tend to be strengths of observational
and other non-RCT research designs [98,100–106]. Table 2
outlines how non-RCT studies could offset some of the
limitations of RCTs. Silverman [103] summarizes that non-
RCTs can compliment RCTs by assessing an interventions’
effect in the real world, “by considering efﬁcacy outcomes,
safety, tolerability, and patient compliance in large patient
populations and by using clinically relevant long-term out-
comes” (p. 114). The frequent failure to include non-RCT
studies in the evidence-base for clinical guidelines is prob-
lematic.
4.2. Conﬂicts of interest
The second major issue in clinical guidelines is conﬂicts
of interest (COI), which have been found in all levels of clin-
ical research and the guidelines that utilize that research.
At the regulatory level, experts and voting members on
advisory committees for the FDA body that reviews new
drug applications – the Center for Drug Evaluation and
Research (CDER) – have connections with pharmaceutical
companies [107,108]. Lurie et al. [108] report that COIs are
“common, often of considerable monetary value, and rarely
result in recusal of advisory committee members” (1921).
The CDER itself receives over one-half of its funding from
pharmaceutical companies [107].
At the trial level, pharmaceutical companies fund
approximately 75% of clinical drug trials published in top
medical journals [107]. A third of this funding goes to uni-
versities and academic medical centers, while the rest goes
to for-proﬁt research companies.
Pharmaceutical companies not only fund clinical
research, they manage it from design conception through
publication – what has come to be known as “ghost
management” of drug research [109–113]. Pharmaceuti-
cal company statisticians design the trial and perform the
analysis, but are not usually listed as an author. Hired med-
ical writers produce ﬁrst drafts and edit papers. Academics
are asked or paid to author the ﬁnal product. Multiple
manuscripts will be written from one study, and com-
munication experts help move manuscripts through the
publication process. An example is the publication record
of Zoloft, in which 85 manuscripts, which were written by
one medical communications company between 1998 and
2001, were more predominantly published and cited than
other manuscripts on Zoloft in that period [113].
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Table 2
Strengths and limitations of RCT and non-RCT research designs.
RCT Non-RCT
Strength Limitation Strength Limitation
Causation Possible to ascertain with
some conﬁdence.
True causal relationship
subject to other
methodological issues
listed below.
Weak support for causation if
longitudinal, instrumental
variable, propensity score, or
other special design is used.
Generally not possible to
ascertain d/t selection
bias and confounders.
Choice  of sample Randomization allows for
assumption of equivalence
between groups.
Use of narrow and select
sample in order to
determine efﬁcacy.
Can be epidemiological sample
from entire population
receiving the intervention. Can
be a large and broad
population.
Lack of randomization
means that groups
cannot be assumed to be
equivalent.
Choice  of outcomes Some use of clinical
endpoints.
Frequent use of surrogate
end points.
Outcomes usually focus on
clinical endpoints such as
mortality, quality of life and
adverse events.
Consistency of research
design & outcomes
With ethical oversight and
transparency, the original
design & outcomes
measures can be
maintained.
Research design &
outcomes may  change
during the study.
With ethical oversight and
transparency, data dredging
can be avoided.
Data dredging may
occur.
Time  horizon May  include
pre-intervention period.
Studies commonly run
for short time.
Population can be studied
having received the
intervention for a long time
period.
Often entails the use of
secondary data with no
pre-intervention data.
Participation Attrition of participants
can be addressed with
special designs.
Attrition of participants
is a common problem.
Attrition of participants can be
addressed with special designs
and statistical methods.
Attrition of participants
is a common problem.
Reporting of results Reporting of all results can
occur with ethical
oversight and
transparency.
Negative or insigniﬁcant
results may not be
published.
Reporting of all results can
occur with ethical oversight
and transparency.
Negative or insigniﬁcant
results may not be
published.
Reporting of risk Absolute risk can be
reported.
Results are commonly
reported as relative risk.
Absolute risk can be reported. Results are commonly
reported as relative risk.
 due to
ple.External validity Can be improved with a
more representative
sample.
Can be weak
narrow sam
At the meta-analysis level, COI can enter into the anal-
ysis, ﬁrst, by using individual studies that have COIs, and
second, by COIs among meta-analysis authors themselves.
We saw that this was the case for the meta-analyses on
statins discussed earlier. Meta-analyses often do not iden-
tify COIs of the studies in the analysis, but even if they
do, they do not necessarily remove the studies from the
analysis [114,115].
At the guideline level, a number of studies report that
a signiﬁcant percentage of guideline authors have ﬁnan-
cial ties to the pharmaceutical industry [116–120], even as
high as 91% and 94% in two U.S. guidelines [120]. Financial
ties can be ﬁnancial support for research, stock ownership,
employment, being a speaker for, or consultation with a
pharmaceutical company [112,116,118,119]. Authors can
have ties with a number of different pharmaceutical com-
panies (Choudhry et al. [116] found 10.5 on average; [116]
Norris et al. [119] found two to ten or more), including with
companies whose drugs are recommended in the guide-
lines (59% in Choudhry et al. [116]). Norris et al. [120]
reported that of the guidelines they examined, 56% of the
manufacturers of recommended drugs had authors with a
ﬁnancial interest in the company [119]. It should be noted
that the actual amount of COI may  be more since COI is
not always identiﬁed, and if authors are queried, not all
respond.Can be strong if data includes a
representative sample from
population of interest.
Often dependent upon
existing data which may
not be representative.
Guideline COIs exist internationally on many different
conditions. For example, guidelines for type 2 diabetes and
Alzheimer’s disease in France were withdrawn in 2011 due
to conﬂicts of interest that had been undeclared [121].
Nearly half of all authors of 297 German guidelines in 2011
had ﬁnancial COI [122]. In a study of psychiatric guidelines
by Cosgrove et al. [117] 100% of members had ﬁnancial ties
to pharmaceutical companies. Each author had an average
of 20.5 relationships [117]. A study of U.S. and Canadian
guidelines for diabetes and hyperlipidemia found that only
29% of panelists potentially had no ﬁnancial ties [123].
Cardiovascular disease guidelines fall into this pattern.
We already noted that the 2013 cholesterol guidelines had
signiﬁcant COI, but this is not a new phenomenon. Many
of the authors and sponsors (including the ACC and AHA)
of prior CVD guidelines have had ﬁnancial ties to pharma-
ceutical and other companies [124,125]. Eight of the nine
authors of the 2004 cholesterol lowering guidelines had
ﬁnancial ties to statin makers [107]. A study by Mendelson
et al. [118] of 17 ACC/AHA guidelines through 2008 found
that 56% of 498 guideline committee members disclosed
COIs. The connections with industry were not just about
research: a signiﬁcant number of committee members
engaged in promotional speaking for, and had stock owner-
ship in, companies producing products recommended by
the committee [118]. As Nissen [126] comments:
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. . .no conceivable logic can defend the practice of
including promotional speakers and stockholders on
CPG writing committees. Participants in speaker’s
bureaus essentially become temporary employees of
industry, whose duty is the promotion of the company’s
products. . . To allow such individuals to write CPGs
deﬁes logic (584–585) [126].
COI is not independent of research biases, but instead
ay  contribute to those biases. There is evidence that
OI impacts individual study results, synthesis results, and
uideline recommendations. Clinical drug trials funded by
harmaceutical companies are less likely to be published
127], and if published more likely to have outcomes favor-
ng the company [127–130]. A recent Cochrane review
ound that industry-supported clinical trials and meta-
nalyses of those trials are signiﬁcantly more likely than
on-commercially funded studies to report positive efﬁ-
acy and safety results [131]. A correlation has been found
etween guideline committee members with ties to phar-
aceutical companies and guidelines that have expanded
isease categories [132]. Cosgrove, et al. [117] found that
nder conditions of signiﬁcant COI less than half of the
uidelines for psychiatric conditions met  criteria for high
uality [117].
. Pharmaceuticalization of clinical guidelines?
When commercial interests inﬂuence the design of the
research protocol, the selection of research subjects, the
conduct of the trial, the collection of data, the interpre-
tation of results, and the publication of the outcome,
there is good reason to worry about the integrity of the
process that produces medical evidence ([133], p. 2698).
It has been noted that the biases and conﬂicts of
nterest inherent in the evidence base of clinical guide-
ines support an approach to healthcare that expands the
oundaries of “disease” and emphasizes the use of pharma-
euticals and other medical products to treat those diseases
109,134,135]. Environmental, socio-economic, and life-
tyle components of maintaining health and preventing
llness are often not part of this research or the guidelines
hat emerge from it.
An example of this trend can be found in a 2013 study
y Moynihan et al. [132]. Out of 16 clinical guidelines on 14
ommon conditions from 2000 to 2013, ten recommended
idening and one narrowing the deﬁnitions of disease. Five
ere unclear. Widening included creating “predisease,”
owering diagnostic thresholds, and proposing earlier or
ifferent diagnostic methods [132]. None of the guidelines
hat proposed widening the disease categories examined
ny adverse outcomes coming from the change. Of the 14
uidelines that disclosed COI, 75% of the authors on average
ad ties to industry.
Speciﬁc examples of this trend include the clinical
uidelines for diabetes, depression, and CVD in the U.S. In
he diabetes guidelines normal blood glucose targets have
een lowered over time so that more individuals now are
onsidered diabetic or prediabetic and need to be placed
n medication [124,136]. Depression guidelines recom-
end that mild depression be treated with antidepressants120 (2016) 797–808 803
even though there is not enough evidence to support this
recommendation [134]. CVD guidelines have over time rec-
ommended lower and lower LDL or total cholesterol levels
until the 2013 guideline, which switched to a risk algo-
rithm at a low level of risk that resulted in an even broader
population considered to be at risk [136,137].
The trend to redeﬁne the boundaries of disease and
medical care has engendered a number of labels. The con-
cept of “disease-mongering” or “selling of illness” describes
the tendency to move formerly healthy biological param-
eters and conditions into the realm of disease [137], while
the related labels of “medicalization” and “pharmaceu-
ticalization” describe the processes of applying medical
products and drugs to treat those diseases [138–141].
With the concept of disease mongering, normal char-
acteristics of aging and health problems amenable to
non-pharmaceutical interventions (such as low risk fac-
tors for chronic diseases) are considered to be “widespread,
severe and treatable with pills [137]. “Examples include
high cholesterol, osteoporosis, sexual dysfunctions, and
attention deﬁcit hyperactivity disorder [142].
With the concept of medicalization, an aspect of health
is deﬁned in medical terms, such as an illness, and is
treated with a medical intervention, often pharmaceuticals
[139,140]. Widening diagnostic criteria for ADHD and bi-
polar disorders are examples in which concerns exist that
the thresholds indicating abnormalities have been set too
low [138].
Pharmaceuticalization is the “process by which social,
behavioral or bodily conditions are treated or deemed to be
in need of treatment with medical drugs”(604) [138]. The
expanding markets for antidepressants, mood stabilizers
and antipsychotics, and their off-label utilization (market-
ing the drugs for conditions they have not been approved
for), have been cited as examples of this trend [138]. Most
germane to our case study of cholesterol guidelines, Pol-
lock and Jones [143] discuss whether the growth in statin
prescriptions is a pharmaceuticalization of coronary artery
disease, but they also bring into the picture the possibil-
ity of a “surgicalization” of CVD, with the increasing use of
bypass surgery and angioplasty [143].
When it comes to the role of clinical guidelines in all
this, the issue may  be more complex than a simple guide-
line reinforcement of these tendencies. Guideline changes
may  be instrumental to these developments in that they rec-
ommend redeﬁning disease to exist at low levels of clinical
symptoms and to need medical intervention, the simplest
and most efﬁcacious to be pharmaceuticals [135,143]. Since
providers rely upon guidelines for their practice, these
developments in clinical guidelines could play a signiﬁcant
role in perpetrating the selling of illness and the medical-
ization/pharmaceuticalization of medical care.
Clearly, not all medical progress over the past decades
can be placed under these labels. A number of medical pro-
fessionals speak of the changes in medical care in terms
of advances in medicine and the beneﬁts of new drugs and
technology [109]. Under this perspective advances in medi-
cal research enables medical care to be better at diagnosing,
preventing and treating disease. Busﬁeld [109] calls this
perspective the “progressive” model. Similar to the con-
cept of the changes as progressive, others believe that the
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issue is one of “biomedicalism” [138]. That is, healthcare
is proceeding in a positive direction in which health is
improved by the increasing use of technology to prevent
and treat conditions. The more technology, the better.
The reality of clinical research and guidelines no doubt
reﬂects a mixture of these tendencies. The ability to identify
risks of chronic disease and begin preventive interventions
for those diseases before symptoms are felt and serious ill-
ness develops is an important step forward in medical care.
However placing large numbers of individuals on pharma-
ceuticals because they are at a questionably determined
small risk of developing a condition in the future is not a
progressive step forward.
6. Policies for future guideline development
Several policies could be implemented to make clinical
guidelines more evidence based and freer from indus-
try inﬂuence, and therefore reduce the tendencies toward
disease mongering, medicalization and pharmaceutical-
ization. First, the guideline evidence base should be
composed of well-designed and conducted RCTs and non-
RCT studies that assess the treatment effectiveness in
all eligible populations (e.g., low risk, older adults, eth-
nic and racial groups, women, etc.) and over time. RCTs
need to be designed to test drugs on all target popula-
tions, with clinical health outcomes that matter, such as
all-cause mortality, patient-reported outcomes, and side
effects/adverse events [144–146]. Well-conducted obser-
vational studies should be seen as complementary to RCTs,
as in the European and Japanese guidelines [147,148],
providing information about how the recommended treat-
ment affects the population over time. A national or
international registry could be utilized to collect data on
effects and side effects on the population. Medical jour-
nals could devote regular space for the purpose of critically
reviewing the results of published trials [138]. Sharing of
anonymous individual patient data with non-trial inves-
tigators would also aid transparency [44]. Additionally,
studies of lifestyle and socio-economic approaches to
preventing illnesses should be considered in guideline for-
mation.
Many of the biases encountered in clinical research (nar-
row and select samples, changing outcomes during the
study, unpublished negative results) could be minimized
if all trials were required to register their research objec-
tives, outcomes measures and design at the start of the
trial, and all trial results were reported in the registry
[92,149–151]. To some extent this is already a require-
ment of drug regulators in several countries (including the
U.S. FDA) [152], of the International Committee of Medical
Journal Editors [153], and of the signatories to the Dec-
laration of Helsinki for medical research [154]. However,
it has yet to be enforced [152–155]. Negative results of
well designed studies need to be embraced and openly
published, which means that journal editors and review-
ers must be more open to this [149,150]. Many scholars
are also asking for the release of primary source data so
that others can replicate trials and perform patient-level
meta-analyses [131,149,156,157].120 (2016) 797–808
A major focus of policies should be to make guidelines,
and the clinical research they draw from, freer from indus-
try inﬂuence. In the past, COI has been addressed through
declarations, but this is not enough [125,158]. It does not
necessarily eliminate the COI, and in fact may  make matters
worse since it provides the illusion that by declaring COI
the research has not been inﬂuenced by it [159]. Lexchin
and O’Donovan [160] recommend prohibiting conﬂict of
interest altogether, but do not discuss how this is to be
accomplished. Short of prohibition, clinical trial investiga-
tors contact with the pharmaceutical industry should be
limited to obtaining the funding for their trial; in other
words, no speaking engagements, gifts, stock ownership,
employment, or consultation with a pharmaceutical com-
pany. Importantly, the research design, conduct, results,
interpretation and dissemination should remain indepen-
dent of industry management.
7. Conclusion
In summary, there is ongoing controversy over the 2013
cholesterol guidelines in terms of their evidence base for
statin initiation in primary prevention for low risk individ-
uals and their conﬂicts of interest with the pharmaceutical
industry. The cholesterol guidelines are typical of other
clinical guidelines, in which reliance on RCTs and con-
ﬂicts of interest call into question the evidence base for the
recommendations. Based on this problematic evidence, a
number of clinical guidelines, and cholesterol guidelines
in particular, have been expanding disease boundaries and
calling for greater pharmaceutical intervention, calling into
question whether the guidelines are a gain in preven-
tion or in “pharmaceuticalization.” More appropriate and
open development of evidence and guidelines is needed
to ensure that human conditions are properly deﬁned and
treated with the best balance of pharmaceutical, lifestyle,
and other interventions.
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